| Literature DB >> 29075483 |
Fithamlak Bisetegen Solomon1, Fiseha Wadilo2, Efrata Girma Tufa3, Meseret Mitiku4.
Abstract
BACKGROUND: Frequently encountered multidrug-resistant bacterial isolates of P. aeruginosa and A. baumannii are common and prevalent in a hospital environment. The aim of this study was to determine the prevalence and pattern of antibiotic resistance, extended spectrum and metallo beta-lactamase producing P. aeruginosa and A. baumannii isolates from restricted settings of indoor air hospital environment.Entities:
Keywords: A. Baumannii; Airborne; Antibiotic resistance; ESBL; MBL; MDR; P. aeruginosa
Year: 2017 PMID: 29075483 PMCID: PMC5654089 DOI: 10.1186/s13756-017-0266-0
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 4.887
Distribution of airway A. baumannii and P. aeruginosa isolates in wards of WSUTRH
| Wards |
|
| Total isolates |
|---|---|---|---|
| Delivery room | 13 | 4 | 17 |
| Intensive care unit | 21 | 13 | 34 |
| Operation room | 9 | 7 | 16 |
Antibiotic resistance profile of air-borne A. baumannii and P. aeruginosa
| Antibiotics |
|
|
|---|---|---|
| Amikacin | 30 (69.8) | 6 (25) |
| Cefotaxime | 32 (74.4%) | 17 (70.8) |
| Cefepime | 38 (88.4%) | 14 (58.3) |
| Ceftazidime | 28 (65.1) | 7 (29.1) |
| Ciprofloxacin | 38 (88.4%) | 20 (83.3) |
| Gentamicine | 33 (76.7) | 19 (79.1) |
| Ceftriaxone | 36 (83.7) | 19 (79.1) |
| Aztreonam | 19 (44.2) | 14 (58.3) |
| Meropenem | 13 (30.2) | 10 (41.7) |
| Imipenem | 16 (37.2) | 10 (41.7) |
| Trimethoprim-Sulfamethoxazole | 40 (93.0) | 21(87.5) |
ESBL and MBL producing airway A.baumannii isolates in restricted settings of the Hospital
| Number of resistance isolates (%) | |||
|---|---|---|---|
| Antibiotics | Total isolates | ESBL producer | MBL producer |
| Ceftazidime | 28 (65.1) | 19 (79.2) | 8 (61.5) |
| Ceftriaxone | 36 (83.7) | 22 (91.7) | 10 (76.9) |
| Cefepime | 38 (88.4) | 23 (95.8) | 11 (84.6) |
| Cefotaxime | 32 (74.4) | 20 (83.3) | 9 (69.2) |
| Aztreonam | 19 (44.2) | 21 (87.5) | 12 (92.3) |
| Impeniem | 16 (37.2) | 5 (20.8) | 13 (100) |
| Meropenem | 13 (30.2) | 3 (12.5) | 13 (100) |
ESBL and MBL producing airway P. aeruginosa isolates in intensive care unit of the hospital
| Number of resistance isolates (%) | |||
|---|---|---|---|
| Antibiotics | Total isolates | ESBL producer | MBL producer |
| Ceftazidime | 7 (29.1) | 11 (73.3) | 7 (77.8) |
| Ceftriaxone | 19 (79.1) | 13 (86.7) | 8 (88.9) |
| Cefipime | 14 (58.3) | 10 (66.7) | 5 (55.6) |
| Cefotaxime | 17 (70.8) | 11 (73.3) | 8 (77.8) |
| Aztreonam | 14 (58.3) | 10 (66.7) | 9 (100) |
| Impenem | 10 (41.7) | 5 (50.0) | 9 (100) |
| Meropenem | 10 (41.7) | 3 (20.0) | 9 (100) |
Antibiogram of air-borne A. baumannii and P. aeruginosa isolates
| Bacteria | Quantity | Resistance pattern | Frequency | Class |
|---|---|---|---|---|
|
| Max | TMP-SXT, CIP, GEN, CRO, CTX, ATM, FEP, IMP, MEM, CAZ, AMK | 5 | 6 |
| TMP-SXT, CIP, GEN, CRO, CTX, ATM, FEP, IMP, MEM, CAZ | 2 | 6 | ||
| TMP-SXT, CIP, GEN, CRO, CTX, ATM, FEP, IMP, MEM | 2 | 6 | ||
| TMP-SXT,CIP, GEN, CRO, CTX, FEP, IMP, MEM,AMK | 1 | 5 | ||
| TMP-SXT, CIP, GEN, CRO, CTX, ATM, FEP | 4 | 5 | ||
| TMP-SXT, CIP, GEN, CRO, CTX | 3 | 4 | ||
| TMP-SXT, CIP, GEN, CRO, ATM | 1 | 4 | ||
| TMP-SXT, CIP, GEN | 1 | 3 | ||
| Min | TMP-SXT, CIP, CRO | 1 | 3 | |
|
| Max | TMP-SXT, CIP, FEP, CRO, GEN, CTX, AMK, CAZ, ATM, IMP, MEM | 7 | 6 |
| TMP-SXT, CIP, FEP, CRO, GEN, CTX, AMK, CAZ, ATM, IMP | 3 | 6 | ||
| TMP-SXT, CIP, FEP, CRO, GEN, CTX, AMK, CAZ, IMP, MEM | 3 | 5 | ||
| TMP-SXT, CIP, FEP, CRO, GEN, CTX, AMK, CAZ, ATM | 6 | 5 | ||
| TMP-SXT, CIP, FEP, CRO, GEN, CTX, AMK, CAZ | 6 | 4 | ||
| TMP-SXT, CIP, FEP, CRO, GEN, CTX, AMK | 2 | 4 | ||
| TMP-SXT, CIP, FEP, CRO, GEN, CTX | 2 | 4 | ||
| TMP-SXT, CIP, FEP, CRO | 4 | 3 | ||
| Min | TMP-SXT, CIP, FEP | 2 | 3 |
Key: AMK-Amikacin, CTX-Cefotaxime, FEP-cefepime CAZ-Ceftazidime, CIP-Ciprofloxacin GEN-Gentamicine CRO-Ceftriaxone, ATM-Aztreonam, MEM-Meropenem, IMP-Imipenem, TMP-SXT-Trimethoprime-Sulphamethoxazole